drugset / Trial / NCT00522379

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

NCT00522379

Phase 3 Completed 514 enrolled UCB Pharma
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.

Timeline

Start
2007-07
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 2 mg Other
Subject Rotigotine Unknown 4 mg Other
Subject Rotigotine Unknown 6 mg Other
Subject Rotigotine Unknown 8 mg Other

Indications